Sorry for the confusion - saw AML and thought MD anderson first...

First 18 Last

Share
Profile

Follow
DrillDown2014

280 Posts.

66

07/10/24

12:38

Post #: 76008231
Share

Originally posted by Steini: ↑

... but generally the trial patients had lines of treatments before they were eligible for CHM / IMU trials.

Sydney, Australia, 13 September 2023: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the
“Company”), an Australian leader in cell therapy, today announced the execution of a clinical
study agreement with The University of Texas MD Anderson Cancer Center to support the
“ADVENT-AML” Phase 1B study, in which Chimeric’s off-the-shelf universal donor NK cell
therapy CHM 0201 will be evaluated in combination with standard of care therapy for patients
with newly diagnosed Acute Myeloid Leukemia (AML).
The ADVENT-AML (NCT05834244) study is designed to enroll up to 20 subjects with newly
diagnosed AML who are not eligible for intensive chemotherapy or allogeneic stem cell
transplant, following completion of a dose confirmation cohort assessing the safety of this
novel combination treatment in subjects with relapsed or refractory AML.
ADVENT-AML will be the first trial to evaluate the synergy of NK cell therapy in combination
with the current standard of care of Azacitidine with Venetoclax (AZA-VEN). As the trial
progresses beyond dose confirmation, it will also be the first trial to evaluate cellular therapy in
newly diagnosed AML patients.
The study, which has received IND clearance by the FDA and is expected to open to enrollment
at MD Anderson by year end 2023, will be led by Principal Investigator Abhishek Maiti MD,
Assistant Professor in the Department of Leukemia at MD Anderson.
Acute Myeloid Leukemia (AML) is the most common acute leukemia in adults with a median
age at diagnosis between 65-72 years. Despite treatment advances, patients who are not
eligible for intensive chemotherapy or allogeneic stem cell transplant patients have limited
therapeutic options. Outcomes for these high-risk subgroups are poor with median overall
survival (mOS) of 6 to 9 months in the newly diagnosed setting1 and 2.4 months for patients
with relapse or refractory disease². Consequently, novel therapies are urgently needed to
improve outcomes for patients with AML.
“This exciting new clinical trial aligns with the emerging evidence that cell therapies provide the
best clinical outcomes in the earliest line of treatment,” said Jason B Litten, MD, Chief Medical
Officer of Chimeric Therapeutics.
“By combining CHM 0201 with the current standard of care for AML patients we may be able to
significantly enhance the outcomes for these patients.”
Under the terms of the clinical study agreement, Chimeric will provide CHM 0201 study drug as
well as partial financial support for study. In addition to the modest financial support from
Chimeric, the study will be supported by grant funding from multiple funding sources including
Gateway for Cancer Researc

Expand

Sorry for the confusion - saw AML and thought MD anderson first line treatemnet - this still bodes well as Car-T therapies are proven succesful in blood cancers

CHM is here for the solid tumours but have to wait for CLTX and CDH17 data

CHM Price at posting: 1.4¢ Sentiment: None Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

Almonty Industries – Now it is getting critical!

MTM

MTM Crit Metals hits +1,870% returns YoY – but fundamental questions remain

MEM

Many are concerned about global falling birthrates. This diverse stock has solutions

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

ASX Market Close: IT surges as Miners dumped | June 18, 2025

First 18 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 0.4¢		Change 0.000(0.00%)		Mkt cap ! $8.060M

Open	High	Low	Value	Volume
0.4¢	0.4¢	0.4¢	$69.79K	17.44M

Buyers (Bids)

No.	Vol.	Price($)
40	26298938	0.3¢

Sellers (Offers)

Price($)	Vol.	No.
0.4¢	9548289	12

View Market Depth

No.	Vol.	Price($)
40	26298938	0.003
16	13800507	0.002
10	50600000	0.001
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.004	9548289	12
0.005	14771167	22
0.006	13747410	16
0.007	4700000	4
0.008	8542434	6

Last trade - 16.10pm 18/06/2025 (20 minute delay)

CHM (ASX) Chart

Sorry for the confusion - saw AML and thought MD anderson first...

Almonty Industries – Now it is getting critical!

MTM Crit Metals hits +1,870% returns YoY – but fundamental questions remain

Many are concerned about global falling birthrates. This diverse stock has solutions

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

ASX Market Close: IT surges as Miners dumped | June 18, 2025

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Sorry for the confusion - saw AML and thought MD anderson first...

Top Stories

Almonty Industries – Now it is getting critical!

MTM Crit Metals hits +1,870% returns YoY – but fundamental questions remain

Many are concerned about global falling birthrates. This diverse stock has solutions

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

ASX Market Close: IT surges as Miners dumped | June 18, 2025

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News